Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Clearside Biomedical, Inc.
  6. Summary
    CLSD   US1850631045

CLEARSIDE BIOMEDICAL, INC.

(CLSD)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
1.330 USD    0.00%
2022Clearside Biomedical, Inc.(NasdaqGM:CLSD) dropped from NASDAQ Biotechnology Index
CI
2022Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022
AQ
2022North American Morning Briefing: Fed Hopes, China -3-
DJ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/23/2023 01/24/2023 01/25/2023 01/26/2023 01/27/2023 Date
1.51(c) 1.45(c) 1.32(c) 1.33(c) 1.33(c) Last
48 279 113 822 203 579 91 386 121 755 Volume
+0.67% -3.97% -8.97% +0.76% 0.00% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1,09 M - -
Net income 2022 -30,8 M - -
Net cash position 2022 45,3 M - -
P/E ratio 2022 -2,60x
Yield 2022 -
Sales 2023 0,44 M - -
Net income 2023 -34,8 M - -
Net cash position 2023 12,9 M - -
P/E ratio 2023 -2,28x
Yield 2023 -
Capitalization 80,1 M 80,1 M -
EV / Sales 2022 31,7x
EV / Sales 2023 152x
Nbr of Employees 34
Free-Float 88,9%
More Financials
Company
Clearside Biomedical, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS). Its SCS injection platform utilizing its SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted delivery of a variety of therapies to the macula, retina or choroid to preserve and improve... 
Read more
More about the company
Ratings of Clearside Biomedical, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about CLEARSIDE BIOMEDICAL, INC.
2022Clearside Biomedical, Inc.(NasdaqGM:CLSD) dropped fr..
CI
2022Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Con..
AQ
2022North American Morning Briefing: Fed Hopes, China -3-
DJ
2022Needham Upgrades Clearside Biomedical to Buy Rating From Hold, Price Target is $5
MT
2022Stifel Upgrades Clearside Biomedical to Buy From Hold, Price Target is $8
MT
2022Wedbush Lowers Clearside Biomedical's Price Target to $6 From $9, Keeps Outperform Rati..
MT
2022Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Co..
AQ
2022Clearside Biomedical Retinal Disease Treatment Candidate Meets Primary Endpoint in Phas..
MT
2022Clearside Biomedical, Inc. : Results of Operations and Financial Condition, Regulation FD ..
AQ
2022Transcript : Clearside Biomedical, Inc., Q3 2022 Earnings Call, Nov 09, 2022
CI
2022CLEARSIDE BIOMEDICAL, INC. Management's Discussion and Analysis of Financial Condition..
AQ
2022Clearside Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
2022Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corpor..
AQ
2022Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effe..
AQ
2022Clearside Biomedical, Inc. Announces Positive Results in Safety, Durability and Biologi..
CI
More news
News in other languages on CLEARSIDE BIOMEDICAL, INC.
2022Le candidat au traitement de la maladie rétinienne de Clearside Biomedical atteint le c..
2022Clearside Biomedical, Inc. annonce ses résultats pour le troisième trimestre et les neu..
2022Clearside Biomedical, Inc. annonce des résultats positifs en matière d'innocuité, de du..
2022Clearside Biomedical, Inc. annonce ses résultats pour le deuxième trimestre et le semes..
2022Clearside Biomedical, Inc. conclut un accord de financement non dilutif avec Healthcare..
More news
Analyst Recommendations on CLEARSIDE BIOMEDICAL, INC.
More recommendations
ETFs positioned on CLEARSIDE BIOMEDICAL, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
IShares Micro-Cap ETF - USD0.02%1.46%United_States
IShares Nasdaq US Biotechnology (D) - USD0.01%1.83%United_States
IShares Nasdaq US Biotechnology - USD0.01%1.78%United_States
IShares Biotechnology ETF - USD0.01%1.30%-NC
Invesco Nasdaq Biotechnology ETF - USD0.01%1.95%-United_States
More ETFs positioned on CLEARSIDE BIOMEDICAL, INC.
Chart CLEARSIDE BIOMEDICAL, INC.
Duration : Period :
Clearside Biomedical, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CLEARSIDE BIOMEDICAL, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 1,33 $
Average target price 6,40 $
Spread / Average Target 381%
EPS Revisions
Managers and Directors
George M. Lasezkay President, Chief Executive Officer & Director
Charles A. Deignan Chief Financial Officer
William D. Humphries Chairman
Rafael V. Andino Vice President-Engineering & Manufacturing
Thomas A. Ciulla Chief Medical & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
CLEARSIDE BIOMEDICAL, INC.18.75%80
VERTEX PHARMACEUTICALS11.16%82 513
REGENERON PHARMACEUTICALS, INC.2.88%79 336
WUXI APPTEC CO., LTD.20.37%42 407
BIONTECH SE-4.37%34 912
BEIGENE, LTD.18.12%27 008